Full Press Release Details
USANA Health Sciences Reports First Quarter Results
SALT LAKE CITY--(BUSINESS WIRE)--April 21, 2020--USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal first quarter ended March 28, 2020.
Key Financial & Operating Highlights
Global manufacturing and distribution remain fully operational.
Continued consumer demand and a successful promotion combine to generate $266.6 million in net sales during the quarter.
Company is following guidelines from government and health officials, to keep employees safe, including a work-from-home strategy for most employees and additional safety precautions for manufacturing and distribution employees.
Associates pivot to continue holding meetings and selling virtually/on-line.
Updated 2020 outlook reflects impact of a stronger U.S. dollar and continued uncertainty surrounding COVID-19.
Q1 2020 Financial Performance
| Consolidated Results | ||
| Net Sales | $266.6 million | -2.3% vs. prior-year quarter +0.1% constant currency vs. prior-year quarter -$6.6 million fx impact, or -2.4% |
| Diluted EPS | $1.23 | +21.8% vs. prior-year quarter Diluted shares of 21.6 million, -9.9% |
| Active Customers | 573,000 | -2.2% vs. prior-year quarter |
| Cash & Cash Equivalents | $194.1 million |
"During this unprecedented period, we extend our gratitude to medical personnel, health officials, government leaders and volunteers around the world who are working tirelessly to respond to the COVID-19 pandemic," said Kevin Guest, Chief
Executive Officer. "The health, wellness and safety of our employees, Associates and customers around the world remain our top priorities. Accordingly, we have modified our go-to-market strategies and operations in each of our markets to comply
with guidelines from government and health officials. The most significant modifications we have made relate to positioning the majority of our employees to work from home and supporting our sales force to enhance their ability to run their
businesses virtually through social media and conference calling platforms. Although these modifications, and COVID-19 in general, negatively impacted our business during the quarter, strong consumer demand for our high-quality, essential,
health products and successful promotions helped us deliver operating results moderately ahead of our expectations."
"Importantly, our manufacturing facilities in the U.S. and China remain fully operational to date, and we have experienced no meaningful disruptions to our world-wide supply chain. While we have always maintained high standards for safety and
sanitation in manufacturing, we have raised those standards with additional measures - including body temperature monitoring, social distancing, and mandatory use of face masks - that are now recommended by government health agencies. Moreover,
in certain markets we have temporarily closed product will-call centers and are instead offering curbside delivery and subsidized shipping to customers."
Q1 2020 Regional Results:
| Asia Pacific Region | ||
| Net Sales | $215.6 million | -2.4% vs. prior-year quarter Constant currency net sales: +0.5% -$6.4 million fx impact, or -2.9% 80.9% of consolidated net sales |
| Active Customers | 449,000 | -2.2% vs. prior-year quarter |
| Asia Pacific Sub-Regions | ||
| Greater China | ||
| Net Sales | $131.4 million | -8.8% vs. prior-year quarter Constant currency net sales: -6.3% |
| Active Customers | 277,000 | -8.9% vs. prior-year quarter -4.5% sequentially |
| North Asia | ||
| Net Sales | $27.3 million | +22.6% vs. prior-year quarter Constant currency net sales: +29.5% |
| Active Customers | 57,000 | +29.5% vs. prior-year quarter +1.8% sequentially |
| Southeast Asia Pacific | ||
| Net Sales | $56.9 million | +4.4% vs. prior-year quarter Constant currency net sales: +6.5% |
| Active Customers | 115,000 | +3.6% vs. prior-year quarter +1.8% sequentially |
| Americas and Europe Region | ||
| Net Sales | $51.0 million | -2.1% vs. prior-year quarter Constant currency net sales: -1.6% 19.1% of consolidated net sales |
| Active Customers | 124,000 | -2.4% vs. prior-year quarter -2.4% sequentially |
Mr. Guest continued, "While many of our Associates have transitioned over the last several years to doing business online through social media, person-to-person and face-to-face selling is still an important part of our business and direct
selling in general. Consequently, the social distancing and stay-at-home orders put in place across all of our markets began to affect our momentum and operating results late in the first quarter and are expected to continue to impact our
results throughout the year. For instance, we chose to cancel several significant in-person Associate events and incentive trips during the first quarter and have either cancelled upcoming events or changed them to virtual events. The extent of
the disruption to our business in each of our markets going forward is difficult to estimate and will depend on many factors, many of which are outside of our control. Importantly, however, we have responded to these challenges by supporting
our Associates in operating their businesses virtually. I remain confident in the strength of USANA's underlying business, the importance of our products for health and wellness, and the resilience and adaptability of our Associates. I also
believe that USANA will emerge from these unprecedented times stronger than ever."
During the quarter, the Company repurchased approximately 785,000 shares of common stock for a total of $57 million. As of March 28, 2020, there was approximately $73 million remaining under the current share repurchase authorization. The
Company ended the quarter with $194.1 million in cash and cash equivalents and no debt. While the Company expects to continue to fund its business with cash from operations, following the end of the first quarter, the Company drew $60 million
on its line of credit to ensure availability of additional liquidity under its credit facility. Additionally, to further enhance its financial flexibility, the Company has temporarily suspended its share repurchase program and is taking steps
to align spending with sales performance and defer non-essential capital investments.
Doug Hekking, Chief Financial Officer, said, "Given the financial strength of our business, we are confident that we will be able to maintain adequate liquidity and flexibility to successfully navigate through the current crisis and pursue
our strategic plans."
The Company is updating its consolidated net sales and earnings per share outlook for fiscal year 2020. The Company's updated guidance reflects the negative impact from a strengthening U.S. dollar as well as continued uncertainty surrounding
the COVID-19 pandemic.
| Fiscal Year 2020 Outlook | ||
| Revised Range | Previous Range | |
| Consolidated Net Sales | $1.00 - $1.08 billion | $1.03 - $1.13 billion |
| Diluted EPS | $4.00 - $4.90 | $4.10 - $4.90 |
"Net sales guidance has been adjusted to reflect an unfavorable shift in currency exchange rates by an estimated $25 million, as well as an adjustment to reflect our current assessment of future sales," added Mr. Hekking. "As a result of a
lower effective tax rate (32.0%) and a lower diluted share count (21.1 million shares), diluted earnings per share changed modestly from previously issued guidance."
Management Commentary Document and Conference Call
For more information on the Company's operating results, please see the "Management Commentary, Results and Outlook" document, which has been posted on the Company's website (http://ir.usana.com) under the "Investor Relations" section of the
site. USANA will hold a conference call and webcast to discuss today's announcement with investors on Wednesday, April 22, 2020 at 11:00 AM Eastern Time. Investors may listen to the call by accessing USANA's website at http://ir.usana.com.
The call will consist of brief opening remarks by the Company's management team, before moving directly into questions and answers.
Non-GAAP Financial Measures
The Company prepares its financial statements using U.S. generally accepted accounting principles ("GAAP"). Constant currency net sales, earnings, EPS and other currency-related financial information (collectively, "Financial Results") are
non-GAAP financial measures that remove the impact of fluctuations in foreign-currency exchange rates ("fx") and help facilitate period-to-period comparisons of the Company's Financial Results that we believe provide investors an additional
perspective on trends and underlying business results. Constant currency Financial Results are calculated by translating the current period's Financial Results at the same average exchange rates in effect during the applicable prior-year period
and then comparing this amount to the prior-year period's Financial Results.
Internal Investigation of China Operations
As the Company first disclosed in February 2017, it is voluntarily conducting an internal investigation of its China operations, BabyCare Ltd. The investigation focuses on compliance with the Foreign Corrupt Practices Act and certain conduct
and policies at BabyCare, including BabyCare's expense reimbursement policies. The Audit Committee of the Company's Board of Directors has assumed direct responsibility for reviewing these matters and has hired experienced counsel to conduct
the investigation. While the Company does not believe that the subject amounts are quantitatively material, or will materially affect its financial statements, it cannot currently predict the outcome of the investigation on its business,
results of operations, or financial condition. The Company's internal investigation is substantially complete, however the Company continues to cooperate with the Securities and Exchange Commission and the United States Department of Justice.
The Company cannot currently predict the duration, scope, or result of the investigation.
USANA develops and manufactures high-quality nutritional supplements, healthy foods and personal care products that are sold directly to Associates and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong
Kong, China, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Philippines, the Netherlands, the United Kingdom, Thailand, France, Belgium, Colombia, Indonesia, Germany, Spain, Romania, and Italy. More information on USANA can be
found at www.usana.com.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these
forward-looking statements, which involve a number of risks and uncertainties, including: uncertainty related to the magnitude, scope and duration of the impact of the COVID-19 pandemic ("COVID-19") to our business, operations and financial
results; the further spread of, and regulatory measures or voluntary actions that may be put in place to limit the spread of, COVID-19 in the markets where we operate, including restrictions on business operations, shelter at home, or social
distancing requirements; the potential for a resurgence of COVID-19 spread in any of our markets in the future; the impact of COVID-19 on the domestic and world economies, including any negative impact on discretionary spending, consumer
demand, and consumer behavior in general; regulatory risk in China in connection with the health products and direct selling business models; regulatory risk in the United States in connection with the direct selling business model; potential
negative effects of material breaches of our information technology systems to the extent we experience a material breach; material failures of our information technology systems; global economic conditions generally; reliance upon our network
of independent Associates; risk associated with governmental regulation of our products, manufacturing and direct selling business model; adverse publicity risks globally; risks associated with our international expansion and operations;
uncertainty relating to the fluctuation in U.S. and other international currencies; and risks associated with the internal investigation into BabyCare's operations. The contents of this release should be considered in conjunction with the risk
factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission. The forward-looking statements in this press release set forth our beliefs as of the date hereof. We do not
undertake any obligation to update any forward-looking statement after the date hereof or to conform such statements to actual results or changes in the Company's expectations, except as required by law.
| USANA Health Sciences, Inc. | |||
| Consolidated Statements of Operations | |||
| (In thousands, except per share data) | |||
| (Unaudited) | |||
| Quarter Ended | |||
| 28-Mar-20 | 30-Mar-19 | ||
| Net sales | $ 266,619 | $ 272,990 | |
| Cost of sales | 46,059 | 45,901 | |
| Gross profit | 220,560 | 227,089 | |
| Operating expenses | |||
| Associate incentives | 116,069 | 122,530 | |
| Selling, general and administrative | 65,479 | 69,555 | |
| Earnings from operations | 39,012 | 35,004 | |
| Other income (expense) | 151 | 1,290 | |
| Earnings before income taxes | 39,163 | 36,294 | |
| Income taxes | 12,611 | 12,122 | |
| NET EARNINGS | $ 26,552 | $ 24,172 | |
| Earnings per share - diluted | $ 1.23 | $ 1.01 | |
| Weighted average shares outstanding - diluted | 21,551 | 23,927 |
| USANA Health Sciences, Inc. | |||
| Consolidated Balance Sheets | |||
| (In thousands) | |||
| (Unaudited) | |||
| As of | As of | ||
| ASSETS | 28-Mar-20 | 28-Dec-19 | |
| Current Assets | |||
| Cash and cash equivalents | $ 194,098 | $ 234,830 | |
| Inventories | 60,568 | 68,905 | |
| Prepaid expenses and other current assets | 32,097 | 25,544 | |
| Total current assets | 286,763 | 329,279 | |
| Property and equipment, net | 97,246 | 95,233 | |
| Goodwill | 16,493 | 16,636 | |
| Intangible assets, net | 29,071 | 29,840 | |
| Deferred income taxes | 2,756 | 3,090 | |
| Other assets | 41,421 | 42,856 | |
| Total assets | $ 473,750 | $ 516,934 | |
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||
| Current Liabilities | |||
| Accounts payable | $ 11,824 | $ 12,525 | |
| Other current liabilities | 112,680 | 123,573 | |
| Total current liabilities | 124,504 | 136,098 | |
| Deferred income taxes | 13,730 | 10,282 | |
| Other long-term liabilities | 17,908 | 18,842 | |
| Stockholders' equity | 317,608 | 351,712 | |
| Total liabilities and stockholders' equity | $ 473,750 | $ 516,934 |
| USANA Health Sciences, Inc. | ||||||||||||||||||||||
| Sales by Region | ||||||||||||||||||||||
| (unaudited) | ||||||||||||||||||||||
| (in thousands) | ||||||||||||||||||||||
| Quarter Ended | ||||||||||||||||||||||
| 28-Mar-20 | 30-Mar-19 | Change from prior year | Currency impact on sales | % change excluding currency impact | ||||||||||||||||||
| Asia Pacific | ||||||||||||||||||||||
| Greater China | $ 131,432 | 49.3 | % | $ 144,153 | 52.8 | % | $ (12,721 | ) | (8.8 | %) | $ (3,708 | ) | (6.3 | %) | ||||||||
| Southeast Asia Pacific | 56,922 | 21.4 | % | 54,515 | 20.0 | % | 2,407 | 4.4 | % | (1,126 | ) | 6.5 | % | |||||||||
| North Asia | 27,251 | 10.2 | % | 22,228 | 8.1 | % | 5,023 | 22.6 | % | (1,538 | ) | 29.5 | % | |||||||||
| Asia Pacific Total | 215,605 | 80.9 | % | 220,896 | 80.9 | % | (5,291 | ) | (2.4 | %) | (6,372 | ) | 0.5 | % | ||||||||
| Americas and Europe | 51,014 | 19.1 | % | 52,094 | 19.1 | % | (1,080 | ) | (2.1 | %) | (271 | ) | (1.6 | %) | ||||||||
| $ 266,619 | 100.0 | % | $ 272,990 | 100.0 | % | $ (6,371 | ) | (2.3 | %) | $ (6,643 | ) | 0.1 | % |
| Active Associates by Region (1) | |||||||||
| (unaudited) | |||||||||
| As of | |||||||||
| 28-Mar-20 | 30-Mar-19 | ||||||||
| Asia Pacific | |||||||||
| Greater China | 95,000 | 33.9 | % | 109,000 | 36.9 | % | |||
| Southeast Asia Pacific | 85,000 | 30.4 | % | 90,000 | 30.5 | % | |||
| North Asia | 38,000 | 13.6 | % | 31,000 | 10.5 | % | |||
| Asia Pacific Total | 218,000 | 77.9 | % | 230,000 | 77.9 | % | |||
| Americas and Europe | 62,000 | 22.1 | % | 65,000 | 22.1 | % | |||
| 280,000 | 100.0 | % | 295,000 | 100.0 | % | ||||
| Active Preferred Customers by Region (2) | |||||||||
| (unaudited) | |||||||||
| As of | |||||||||
| 28-Mar-20 | 30-Mar-19 | ||||||||
| Asia Pacific | |||||||||
| Greater China | 182,000 | 62.1 | % | 195,000 | 67.0 | % | |||
| Southeast Asia Pacific | 30,000 | 10.2 | % | 21,000 | 7.2 | % | |||
| North Asia | 19,000 | 6.5 | % | 13,000 | 4.5 | % | |||
| Asia Pacific Total | 231,000 | 78.8 | % | 229,000 | 78.7 | % | |||
| Americas and Europe | 62,000 | 21.2 | % | 62,000 | 21.3 | % | |||
| 293,000 | 100.0 | % | 291,000 | 100.0 | % |
(1) Associates are independent distributors of our products who also purchase our products for their personal use. We only count as active those Associates who have purchased from us any time during the most recent three-month period, either
for personal use or resale.
(2) Preferred Customers purchase our products strictly for their personal use and are not permitted to resell or to distribute the products. We only count as active those Preferred Customers who have purchased from us any time during the most
recent three-month period. China utilizes a Preferred Customer program that has been implemented specifically for that market.